Abstract:Objective:To research the effect of TNF-α inhibitors on hepatitis C virus(HCV) infection in hepatocytes.Methods:Hepatoma Huh7 cells were cultured in vitro.Huh7 cells divided into four groups:untreated group,NFκB inhibitors [6-amino-4-(4-phenoxyphenylethylamino) quinazoline,QNZ] treated group,caffeic acid phenethyl ester (CAPE)) treated group and TNF-o inhibitors (Lenalidomide) treated group.Concentrations of the inhibitors were from 100 μmol/L to 1.28 nmol/L with 5-fold serial dilution in each group.Cell proliferation was observed via CCK8 methods.Huh7 cells pre-treated with inhibitors were followed with HCV infection.The intracellular HCV RNA and protein levels were determined by quantitative PCR and immunofluorescence assay.Results:The absorbance values at 450 nm of 100 μmol/L QNZ treatment group(0.730 ± 0.056) and 100 μmol/L CAPE treatment group(1.040 ±0.014) were lower than those of untreated group (1.190 ± 0.040,P=0.000).The proliferation level of each concentration of Lenalidomide treatment group(100 μmol/L treatment group,1.250 ± 0.016) was similar with untreated group(P=0.306).In terms of antiviral activity,the HCV RNA levels of 100 nmol/L Lenalidomide treatment group[(3.79 ± 0.88) × 105] and QNZ treatment group[(6.64 ±1.11) × 105] were significantly lower than those of untreated group[(1.51 ± 0.45) × 106,P=0.000].CAPE treatment group[(1.61 ± 0.15) × 106] had a similar HCV RNA level with untreated group(P=0.383).Conclusion:TNF-α inhibitor Lenalidomide is less toxic to cells and can inhibit hepatitis C virus infection in hepatocytes.

TNF-α inhibitor suppresses hepatitis C virus infection in hepatocytes in vitro